Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the interest coverage ratio high or low?
The interest coverage ratio of -619.28x is 330% below its 3-year average of -143.93x, near the low end of its 3-year range (-619.28x–-8.45x).
As of the fiscal period ended Saturday, December 31, 2022.
Reported quarterly interest coverage; no daily interpolation. Q4 FY2022 (2022-12-31): -619.28x.
INTEREST COVERAGE RATIO
-619.28x
INTEREST COVERAGE RATIO AVG TTM
N/A
INTEREST COVERAGE RATIO AVG 3Y
N/A
INTEREST COVERAGE RATIO AVG 5Y
N/A
INTEREST COVERAGE RATIO AVG 10Y
N/A
INTEREST COVERAGE RATIO AVG 15Y
N/A
INTEREST COVERAGE RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-6.38x
median of 520 covered companies
CURRENT VS SECTOR MEDIAN
-9614.27%
vs the sector median at left
MaxCyte, Inc.
Market Cap
$113.01M
Interest Coverage Ratio
-619.28x
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$111.94M
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$112.69M
Interest Coverage Ratio
-280.53x
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$112.51M
Interest Coverage Ratio
-415.73x
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$112.69M
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$114.02M
Interest Coverage Ratio
-2256.36x
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$114.06M
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$114.57M
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$115.76M
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | INTEREST COVERAGE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| MaxCyte, Inc. (MXCT) | $113.01M | -619.28x | N/A | N/A | N/A |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $111.94M | N/A | N/A | N/A | N/A |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $112.69M | -280.53x | N/A | N/A | N/A |
| Unicycive Therapeutics, Inc. (UNCY)vs › | $112.51M | -415.73x | N/A | N/A | N/A |
| Foghorn Therapeutics Inc. (FHTX)vs › | $112.69M | N/A | N/A | N/A | N/A |
| Lucid Diagnostics Inc. (LUCD)vs › | $114.02M | -2256.36x | N/A | N/A | N/A |
| Caribou Biosciences, Inc. (CRBU)vs › | $114.06M | N/A | N/A | N/A | N/A |
| Genelux Corporation (GNLX)vs › | $114.57M | N/A | N/A | N/A | N/A |
| Coya Therapeutics, Inc. (COYA)vs › | $115.76M | N/A | N/A | N/A | N/A |
| Apyx Medical Corporation (APYX)vs › | $109.74M | -1.15x | 4.51x | 6.93x | 222.11x |
Interest Coverage
-619.3x
Debt/Equity
0.11
Current Ratio
12.26
Formula: Interest Coverage = EBIT / Interest Expense
Reference ranges:
Note: Interest coverage should be compared with historical interest expense, operating income, and industry capital structure.
Interest Coverage = EBIT / Interest Expense
The interest coverage ratio measures operating earnings relative to interest expense.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | INTEREST COVERAGE RATIO |
|---|---|
| 2022-12-31 | -619.28x |
| 2021-09-30 | -8.45x |
| 2021-06-30 | -334.64x |
| 2021-03-31 | -8.59x |
| 2020-12-31 | -8.49x |
| 2020-09-30 | -10.80x |
| 2020-06-30 | -17.27x |
